$CLGN

COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant (CLGN) reported Q2 2026 financial results, with revenues of $108,000, down from $179,000 in Q2 2025. The company acquired LightSolver, entering the high-performance computing market, and appointed Dr. Ruti Ben Shlomi to its board. CollPlant also continues to focus on regenerative medicine. GAAP net loss for Q2 2026 was $2.7 million, or $1.89 per share.

Original reporting
Published Sep 30, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CLGN
Bearish
high confidence
Mentioned
$CLGN
Relevance
6/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$CLGNBearishMed
01

Why it matters

Earnings miss and higher losses may trigger a sell‑off, but the strategic diversification could attract investors seeking exposure to emerging HPC technologies.

02

Market read

Primary corporate disclosure with new financial metrics and a strategic acquisition; relevant for traders in biotech and emerging tech sectors.

03

What to watch

Cost‑reduction measures and board addition of LightSolver co‑founder may improve operational efficiency over time.

Relevance 6/10Novelty 7/10Timing: post-release today

Background

CollPlant announced Q2 2026 results and the completion of its LightSolver acquisition, expanding into photonic computing while continuing its regenerative medicine focus.

Company-level read

Ticker impact

$CLGNBearishHigh confidence
Context

CollPlant Biotechnologies disclosed Q2 2026 financial results and completed its LightSolver acquisition, providing new revenue, loss and cash flow figures.

Expected impact

likely downward pressure as the market prices in lower revenue and a larger net loss.

Evidence & confidence

Revenue fell 40% YoY and the company posted a larger gross loss; the acquisition adds uncertainty about integration and future cash burn.

Market effects

Highlights challenges in the regenerative medicine sector and may dampen sentiment toward small-cap biotech stocks.

Limited to US and Israeli biotech investors.

Minimal global impact beyond niche biotech investors.

Counterpoint

The acquisition could unlock a new high‑performance computing revenue stream, offering long‑term upside despite short‑term earnings weakness.

Key entities

  • CollPlant Biotechnologies

    US‑listed biotech firm (Nasdaq: CLGN) reporting Q2 results and acquisition.

  • LightSolver

    Photonic computing startup acquired by CollPlant.

Related articles

$CLGNHighAI 8/10

CollPlant Is Acquiring LightSolver- Enters Supercomputing And Photonic Computing Markets

CollPlant (CLGN) is acquiring LightSolver, a developer of photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address computational speed and energy challenges. The deal includes upfront shares, warrants, and milestone-based payments. LightSolver is working with partners like Boeing (BA) to validate its technology, targeting commercial availability by 2028.

$CLGNHighAI 8/10

COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

CollPlant (Nasdaq: CLGN) is acquiring LightSolver, a company developing photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address speed and energy limitations of semiconductor-based computing. The acquisition includes equity and milestone-based warrants. LightSolver is partnering with Boeing (NYSE: BA) and other global leaders for commercial validation. The deal is expected to close this week.

$CLGNMedAI 9/10

CollPlant Biotechnologies (NASDAQ:CLGN) Issues Earnings Results

CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly EPS of -$0.23, slightly above analysts’ -$0.24 consensus, according to Zacks. Revenue was $0.07 million versus an expected $0.46 million. The stock opened at $0.40 and was down 0.7%. MarketBeat data shows a $11.50 consensus target and an average “Hold” rating.